Five Prime Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2001-01-01

Employees: 101

Market Cap: -

Website: http://www.fiveprime.com

Clinical Trials

FPT155 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Biological: FPT155
Biological: pembrolizumab

First Posted Date: 2019-08-30

Last Posted Date: 2024-02-28

Lead Sponsor: Five Prime Therapeutics, Inc.

Target Recruit Count: 80

Registration Number: NCT04074759

Locations: 🇦🇺
Scientia Clinical Research, Randwick, New South Wales, Australia
🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺
St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia

and more 9 locations

An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer

Conditions: Recurrent Bladder Cancer

First Posted Date: 2019-01-11

Last Posted Date: 2021-12-13

Lead Sponsor: Five Prime Therapeutics, Inc.

Registration Number: NCT03801278

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Biological: Bemarituzumab
Drug: Placebo
Drug: Modified FOLFOX6

First Posted Date: 2018-10-03

Last Posted Date: 2024-02-28

Lead Sponsor: Five Prime Therapeutics, Inc.

Target Recruit Count: 155

Registration Number: NCT03694522

Locations: 🇺🇸
Virginia Mason Seattle Main Clinic, Seattle, Washington, United States
🇮🇹
ASST della Valtellina e dell'Alto Lario - PO di Sondrio, Sondrio, Italy
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan

and more 186 locations

FPA150 in Patients With Advanced Solid Tumors

Early Phase 1

Terminated

Conditions: Ovarian Cancer
Breast Cancer
Endometrial Cancer
Advanced Solid Tumors

Interventions: Biological: FPA150
Biological: Pembrolizumab

First Posted Date: 2018-05-02

Last Posted Date: 2024-11-22

Lead Sponsor: Five Prime Therapeutics, Inc.

Target Recruit Count: 95

Registration Number: NCT03514121

Locations: 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 15 locations

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer

Phase 1

Completed

Conditions: Gastrointestinal Cancer
Gastric Cancer
Gastrointestinal Cancer Metastatic

Interventions: Biological: Bemarituzumab
Drug: Modified FOLFOX6

First Posted Date: 2017-11-17

Last Posted Date: 2024-02-28

Lead Sponsor: Five Prime Therapeutics, Inc.

Target Recruit Count: 12

Registration Number: NCT03343301

Locations: 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Marin Cancer Care, Greenbrae, California, United States

and more 4 locations

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

Phase 1

Completed

Conditions: Malignant Glioma
Head and Neck Cancer
Advanced Solid Tumors
Pancreatic Cancer
Renal Cell Carcinoma
Ovarian Cancer
Non-small Cell Lung Cancer

Interventions: Biological: Cabiralizumab
Biological: Nivolumab

First Posted Date: 2015-08-18

Last Posted Date: 2022-03-09

Lead Sponsor: Five Prime Therapeutics, Inc.

Target Recruit Count: 313

Registration Number: NCT02526017

Locations: 🇺🇸
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, United States
🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCLA Hematology/Oncology- Santa Monica, Santa Monica, California, United States

and more 36 locations

Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor

Phase 1

Completed

Conditions: Pigmented Villonodular Synovitis
Tenosynovial Giant Cell Tumor

Interventions: Biological: FPA008

First Posted Date: 2015-06-15

Last Posted Date: 2021-08-31

Lead Sponsor: Five Prime Therapeutics, Inc.

Target Recruit Count: 66

Registration Number: NCT02471716

Locations: 🇫🇷
Centre Léon Bérard, Lyon, France
🇬🇧
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 9 locations

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Transitional Cell Carcinoma of the Bladder
Gastric Cancer
Advanced Solid Tumors

Interventions: Drug: FPA144

First Posted Date: 2014-12-17

Last Posted Date: 2024-06-04

Lead Sponsor: Five Prime Therapeutics, Inc.

Target Recruit Count: 79

Registration Number: NCT02318329

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 23 locations

Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects

Phase 1

Terminated

Conditions: Healthy
Rheumatoid Arthritis

Interventions: Drug: FPA008
Drug: Placebo

First Posted Date: 2013-10-14

Last Posted Date: 2021-12-13

Lead Sponsor: Five Prime Therapeutics, Inc.

Target Recruit Count: 66

Registration Number: NCT01962337

Locations: 🇭🇺
Drug Research Center, Kaposvar, Hungary
🇭🇺
PRA Clinical Unit, Budapest, Hungary
🇵🇱
MedPolina, Poznan, Poland

and more 3 locations

Study of FP-1039 in Subjects With Endometrial Cancers

Phase 2

Withdrawn

Conditions: Endometrial Cancers With FGFR2 Mutations

Interventions: Drug: FP-1039

First Posted Date: 2010-11-19

Last Posted Date: 2021-12-13

Lead Sponsor: Five Prime Therapeutics, Inc.

Registration Number: NCT01244438

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy